Development partners at MEI, Helsinn dump a high-risk PhIII AML study after concluding it would fail survival goal

John Carroll

Editor & Founder

Four years after Switzerland’s Helsinn put $25 million of cash on the table for an upfront and near-term milestone to take MEI Pharma’s drug pracinostat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Development partners at MEI, Helsinn dump a high-risk PhIII AML study after concluding it would fail survival goal

John Carroll

Editor & Founder

Sign up to read this article for free.

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Joe Jimenez's latest Aditum company lines up T cell engager from China

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

John Carroll

Editor & Founder

Sign up to read this article for free.

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Development partners at MEI, Helsinn dump a high-risk PhIII AML study after concluding it would fail survival goal

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Joe Jimenez's latest Aditum company lines up T cell engager from China

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks